$Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias$

Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias

MS-275 is a benzamide derivative with potent histone deacetylase (HDAC) inhibitory and antitumor activity in preclinical models. We conducted a phase 1 trial of orally administered MS-275 in 38 adults with advanced acute leukemias. Cohorts of patients were treated with MS-275 initially once weekly ×...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Blood 2007-04, Vol.109 (7), p.2781-2790
Hauptverfasser:	Gojo, Ivana, Jiemjit, Anchalee, Trepel, Jane B., Sparreboom, Alex, Figg, William D., Rollins, Sandra, Tidwell, Michael L., Greer, Jacqueline, Chung, Eun Joo, Lee, Min-Jung, Gore, Steven D., Sausville, Edward A., Zwiebel, James, Karp, Judith E.
Format:	Artikel
Sprache:	eng
Schlagworte:	Acetylation Adult Aged Aged, 80 and over Antineoplastic Agents - administration & dosage Antineoplastic Agents - pharmacokinetics Antineoplastic Agents - therapeutic use Benzamides - administration & dosage Benzamides - pharmacokinetics Benzamides - therapeutic use Biological and medical sciences Clinical Trials and Observations Enzyme Inhibitors - administration & dosage Enzyme Inhibitors - pharmacokinetics Enzyme Inhibitors - therapeutic use Female Hematologic and hematopoietic diseases Histone Deacetylase Inhibitors Histones - metabolism Humans Leukemia - drug therapy Leukemia - metabolism Male Medical sciences Middle Aged Neoplasm Proteins - metabolism Pyridines - administration & dosage Pyridines - pharmacokinetics Pyridines - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!